Lilly's 2025 guidance of USD 5861 billion implies continued 32% growth momentum, validated by the SURMOUNT-5 Phase 3b head-to-head trial result: Zepbound demonstrated 47% greater relative weight loss compared to Wegovy the most commercially consequential head-to-head data in the obesity market
Thats another reason theyre not going to see the long-term effects. Diede agreed that, at current prices, the economics are difficult to justify purely on cost savings
25 , 26 , 81 Drug Interactions Felbamate can induce or inhibit the metabolism of the older AEDs
This might all sound affordable, but it adds up over the long term
Yarlagadda, V., Medina, R., Wright, G
You can combine both supplements for balanced energy, but no clinical trials have studied this combination specifically